BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
Public ClinicalTrials.gov record NCT05935098. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT05935098
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- BeiGene
- Industry
- Enrollment
- 99 participants
Conditions and interventions
Interventions
- BGB-A3055 Drug
- Chemotherapy Drug
- Tislelizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 20, 2023
- Primary completion
- Jan 26, 2026
- Completion
- Jan 26, 2026
- Last update posted
- Mar 12, 2026
2023 – 2026
United States locations
- U.S. sites
- 6
- U.S. states
- 5
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Advent Health Cancer Institute | Orlando | Florida | 32804-4603 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242-1009 | — |
| John Theurer Cancer Center Hackensack University Medical Center | Hackensack | New Jersey | 07601-2191 | — |
| The University of Texas Md Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
| Next Dallas | Irving | Texas | 75039-2743 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109-4433 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05935098, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 12, 2026 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05935098 live on ClinicalTrials.gov.